Plus Therapeutics, Inc. (NASDAQ:PSTV – Free Report) – Analysts at HC Wainwright issued their FY2028 EPS estimates for Plus Therapeutics in a report released on Friday, November 15th. HC Wainwright analyst S. Lee expects that the company will post earnings of $0.28 per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.00) per share.
Separately, Ascendiant Capital Markets decreased their price objective on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd.
Plus Therapeutics Stock Performance
Plus Therapeutics stock opened at $1.22 on Monday. The firm’s 50 day moving average price is $1.40 and its two-hundred day moving average price is $1.66. Plus Therapeutics has a 1 year low of $1.15 and a 1 year high of $2.67. The firm has a market cap of $7.20 million, a price-to-earnings ratio of -0.48 and a beta of 0.69.
Institutional Investors Weigh In On Plus Therapeutics
A hedge fund recently bought a new stake in Plus Therapeutics stock. AIGH Capital Management LLC acquired a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned approximately 9.98% of Plus Therapeutics at the end of the most recent quarter. 3.28% of the stock is currently owned by institutional investors.
About Plus Therapeutics
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
See Also
- Five stocks we like better than Plus Therapeutics
- What is an Earnings Surprise?
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- ESG Stocks, What Investors Should Know
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- What is the S&P/TSX Index?
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
